AIMS To compare ST-segment elevation myocardial infarction (STEMI) and non-STEMI (NSTEMI) mortality between Sweden and the UK, adjusting for background population rates of expected death, case mix, and treatments. METHODS AND RESULTS National data were collected from hospitals in Sweden [n = 73 hospitals, 180 368 patients, Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART)] and the UK [n = 247, 662 529 patients, Myocardial Ischaemia National Audit Project (MINAP)] between 2003 and 2013. There were lower rates of revascularization [STEMI (43.8% vs. 74.9%); NSTEMI (27.5% vs. 43.6%)] and pharmacotherapies at time of hospital discharge including [aspirin (82.9% vs. 90.2%) and (79.9% vs. 88.0%), β-blockers (73.4% vs. 86.4%) and (65.3% vs. 85.1%)] in the UK compared with Sweden, respectively. Standardized net probability of death (NPD) between admission and 1 month was higher in the UK for STEMI [8.0 (95% confidence interval 7.4-8.5) vs. 6.7 (6.5-6.9)] and NSTEMI [6.8 (6.4-7.2) vs. 4.9 (4.7-5.0)]. Between 6 months and 1 year and more than 1 year, NPD remained higher in the UK for NSTEMI [2.9 (2.5-3.3) vs. 2.3 (2.2-2.5)] and [21.4 (20.0-22.8) vs. 18.3 (17.6-19.0)], but was similar for STEMI [0.7 (0.4-1.0) vs. 0.9 (0.7-1.0)] and [8.4 (6.7-10.1) vs. 8.3 (7.5-9.1)]. CONCLUSION Short-term mortality following STEMI and NSTEMI was higher in the UK compared with Sweden. Mid- and longer-term mortality remained higher in the UK for NSTEMI but was similar for STEMI. Differences in mortality may be due to differential use of guideline-indicated treatments.

中文翻译：

---

842 897个欧洲人的急性心肌梗死后的死亡率统计数据。

目的比较瑞典和英国之间ST段抬高型心肌梗死（STEMI）和非STEMI（NSTEMI）死亡率，并调整预期死亡，病例组合和治疗的背景人群比率。方法和结果国家数据收集自瑞典的医院[n = 73所医院，180 368名患者，根据推荐的治疗方法（SWEDEHEART）对瑞典增强和发展循证医学的Web系统进行了评估]和英国[ 2003年至2013年间，n = 247，662 529名患者，心肌缺血国家审计项目（MINAP）。NSTEMI（27.5％vs. 43.6％）]和出院时的药物治疗，包括[阿司匹林（82.9％vs. 90.2％）和（79.9％vs. 88.0％），β-受体阻滞剂（73.4％vs. 86.4％）和（65.3％与85。1％）]与瑞典相比。英国入院至1个月之间的标准净死亡概率（NPD）较高，STEMI [8.0（95％置信区间7.4-8.5）与6.7（6.5-6.9）]和NSTEMI [6.8（6.4-7.2）与4.9（4.7-5.0）]。在6个月至1年至1年以上的时间内，NSTEMI在英国的NPD仍然较高[2.9（2.5-3.3）对2.3（2.2-2.5）]和[21.4（20.0-22.8）对18.3（17.6- 19.0）]，但对于STEMI来说是相似的[0.7（0.4-1.0）对0.9（0.7-1.0）]和[8.4（6.7-10.1）对8.3（7.5-9.1）]。结论在英国，与瑞典相比，英​​国STEMI和NSTEMI后的短期死亡率更高。在英国，NSTEMI的中长期死亡率仍然较高，但STEMI相似。死亡率差异可能是由于指导性治疗方法的差异使用造成的。英国入院至1个月之间的标准净死亡概率（NPD）较高，STEMI [8.0（95％置信区间7.4-8.5）与6.7（6.5-6.9）]和NSTEMI [6.8（6.4-7.2）与4.9（4.7-5.0）]。在6个月至1年至1年以上的时间内，NSTEMI在英国的NPD仍然较高[2.9（2.5-3.3）对2.3（2.2-2.5）]和[21.4（20.0-22.8）对18.3（17.6- 19.0）]，但对于STEMI来说是相似的[0.7（0.4-1.0）对0.9（0.7-1.0）]和[8.4（6.7-10.1）对8.3（7.5-9.1）]。结论在英国，与瑞典相比，英​​国STEMI和NSTEMI后的短期死亡率更高。在英国，NSTEMI的中长期死亡率仍然较高，但STEMI相似。死亡率差异可能是由于指导性治疗方法的差异使用造成的。英国入院至1个月之间的标准净死亡概率（NPD）较高，STEMI [8.0（95％置信区间7.4-8.5）与6.7（6.5-6.9）]和NSTEMI [6.8（6.4-7.2）与4.9（4.7-5.0）]。在6个月至1年至1年以上的时间里，NSTEMI在英国的NPD仍然较高[2.9（2.5-3.3）对2.3（2.2-2.5）]和[21.4（20.0-22.8）对18.3（17.6- 19.0）]，但对于STEMI来说是相似的[0.7（0.4-1.0）对0.9（0.7-1.0）]和[8.4（6.7-10.1）对8.3（7.5-9.1）]。结论在英国，与瑞典相比，英​​国STEMI和NSTEMI后的短期死亡率更高。在英国，NSTEMI的中长期死亡率仍然较高，但STEMI相似。死亡率差异可能归因于指南指示疗法的不同使用。